Treatment outcomes and the role of surgery in gestational trophoblastic neoplasia: a population-based cohort study
DOI:
https://doi.org/10.2340/1651-226X.2025.43274Keywords:
Gestational trophoblastic disease, surgical treatment, Choriocarcinoma, epithelioid trophoblastic tumour, placental site trophoblastic tumourAbstract
Background and purpose: Cure rates of gestational trophoblastic neoplasia (GTN) are excellent, however the surgical interventions in disease management are not well described. The primary aim of this study was to investigate the incidence and types of surgical procedures used for management of GTN and to report treatment outcomes in a population-based cohort. The secondary aim was to assess the impact of hysterectomy on time to human chorionic gonadotropin (hCG)-normalisation in low-risk GTN.
Material and methods: Medical records of all patients treated for GTN at Karolinska University Hospital, Stockholm, Sweden between 1994 and 2020 were screened for treatment outcomes, types of surgical procedures and complications. Regression models were used to assess if hysterectomy affected time to complete remission in low-risk GTN.
Results and interpretation: Over the 27-year study period, 185 patients with GTN were included. The primary complete remission rate was 98.4% and relapse rate 3.2%. Sixty-four patients (34.6%) underwent at least one surgical procedure; 39/154 (25.3%) of low-risk patients, 17/23 (73.9%) of high-risk patients and all (100%) patients with placental site or epithelioid trophoblastic tumour. No severe complications (Clavien-Dindo ≥3) were observed. Seven of 74 procedures (9.5%) were complicated by bleeding >1,000 mL or surgical site infection. Therapeutic hysterectomy significantly shortened time to hCG-normalisation in the low-risk group (48 vs 74 days, p = 0.002).
This population-based study confirms the excellent cure rates and low relapse rates for GTN. Surgery plays an important role in the management of GTN with low risk of complications. Hysterectomy shortens time to hCG normalisation.
Downloads
References
Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet. 2010;376(9742):717–29.
https://doi.org/10.1016/S0140-6736(10)60280-2 DOI: https://doi.org/10.1016/S0140-6736(10)60280-2
Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obst Gynecol. 2010;203(6):531–9.
https://doi.org/10.1016/j.ajog.2010.06.073 DOI: https://doi.org/10.1016/j.ajog.2010.06.073
Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, et al. Diagnosis and management of gestational trophoblastic disease: 2021 update. Int J Gynaecol Obst. 2021;155(Suppl. 1):86–93.
https://doi.org/10.1002/ijgo.13877 DOI: https://doi.org/10.1002/ijgo.13877
Benedet JL, Bender H, Jones H, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obst. 2000;70(2):209–62.
Goldstein DP, Berkowitz RS. Current management of gestational trophoblastic neoplasia. Hematol Oncol Clin North Am. 2012;26(1):111–31.
https://doi.org/10.1016/j.hoc.2011.10.007 DOI: https://doi.org/10.1016/j.hoc.2011.10.007
Lima LDLA, Padron L, Câmara R, Sun SY, Rezende J, Braga A. The role of surgery in the management of women with gestational trophoblastic disease. Rev Col Brasil Cirurg. 2017;44(1):94–101.
https://doi.org/10.1590/0100-69912017001009 DOI: https://doi.org/10.1590/0100-69912017001009
Bolze P-A, Mathe M, Hajri T, You B, Dabi Y, Schott A-M, et al. First-line hysterectomy for women with low-risk non-metastatic gestational trophoblastic neoplasia no longer wishing to conceive. Gynecol Oncol. 2018;150(2):282–7.
https://doi.org/10.1016/j.ygyno.2018.05.030 DOI: https://doi.org/10.1016/j.ygyno.2018.05.030
Coopmans L, Larsson A, Joneborg U, Lok C, van Trommel N. Surgical management of gestational trophoblastic disease. Gynecol Obst Investig. 2024;89(3):214–29.
https://doi.org/10.1159/000534065 DOI: https://doi.org/10.1159/000534065
Gorun F, Tomescu L, Motoc A, Citu C, Sas I, Serban DM, et al. Clinical features and management of trophoblastic epithelioid tumors: a systematic review. Medicine. 2022;101(30):e29934.
https://doi.org/10.1097/MD.0000000000029934 DOI: https://doi.org/10.1097/MD.0000000000029934
Horowitz NS, Goldstein DP, Berkowitz RS. Placental site trophoblastic tumors and epithelioid trophoblastic tumors: biology, natural history, and treatment modalities. Gynecol Oncol. 2017;144(1):208–14.
https://doi.org/10.1016/j.ygyno.2016.10.024 DOI: https://doi.org/10.1016/j.ygyno.2016.10.024
Seckl MJ, Sebire NJ, Fisher RA, Golfier F, Massuger L, Sessa C, et al. Gestational trophoblastic disease; ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol. 2013;24(Suppl. 6):vi39-50.
https://doi.org/10.1093/annonc/mdt345 DOI: https://doi.org/10.1093/annonc/mdt345
Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24(11):659–67.
https://doi.org/10.1007/s10654-009-9350-y DOI: https://doi.org/10.1007/s10654-009-9350-y
FIGO Oncology Committee. FIGO staging for gestational trophoblastic neoplasia 2000. FIGO Oncology Committee. Int J Gynaecol Obst. 2002;77(3):285–7.
https://doi.org/10.1016/s0020-7292(02)00063-2 DOI: https://doi.org/10.1016/S0020-7292(02)00063-2
Lok C, van Trommel N, Massuger L, Golfier F, Seckl M, Clinical Working Party of the EOTTD. Practical clinical guidelines of the EOTTD for treatment and referral of gestational trophoblastic disease. Eur J Cancer. 2020;130:228–40.
https://doi.org/10.1016/j.ejca.2020.02.011 DOI: https://doi.org/10.1016/j.ejca.2020.02.011
Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.
https://doi.org/10.1097/01.sla.0000133083.54934.ae DOI: https://doi.org/10.1097/01.sla.0000133083.54934.ae
Alifrangis C, Agarwal R, Short D, Fisher RA, Sebire NJ, Harvey R, et al. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J Clin Oncol. 2013;31(2):280–6.
https://doi.org/10.1200/JCO.2012.43.1817 DOI: https://doi.org/10.1200/JCO.2012.43.1817
Newlands ES, Holden L, Seckl MJ, McNeish I, Strickland S, Rustin GJS. Management of brain metastases in patients with high-risk gestational trophoblastic tumors. J Reprod Med. 2002;47(6):465–71.
Flam F, Lundström V. Twenty years’ experience of treating gestational trophoblastic neoplasia in Sweden. Acta Obst Gynecol Scand. 1989;68(1):65–9.
https://doi.org/10.3109/00016348909087692 DOI: https://doi.org/10.3109/00016348909087692
Balachandran K, Salawu A, Ghorani E, Kaur B, Sebire NJ, Short D, et al. When to stop human chorionic gonadotrophin (hCG) surveillance after treatment with chemotherapy for gestational trophoblastic neoplasia (GTN): a national analysis on over 4,000 patients. Gynecol Oncol. 2019;155(1):8–12.
https://doi.org/10.1016/j.ygyno.2019.07.024 DOI: https://doi.org/10.1016/j.ygyno.2019.07.024
Bower M, Newlands ES, Holden L, Short D, Brock C, Rustin GJ, et al. EMA/CO for high-risk gestational trophoblastic tumours: results from a cohort of 272 patients. J Clin Oncol. 1997;15(7):2636–43.
https://doi.org/10.1200/JCO.1997.15.7.2636 DOI: https://doi.org/10.1200/JCO.1997.15.7.2636
Batman S, Skeith A, Allen A, Munro E, Caughey A, Bruegl A. Cost-effectiveness of second curettage for treatment of low-risk non-metastatic gestational trophoblastic neoplasia. Gynecol Oncol. 2020;157(3):711–15.
https://doi.org/10.1016/j.ygyno.2020.03.029 DOI: https://doi.org/10.1016/j.ygyno.2020.03.029
Albright BB, Ellett T, Knochenhauer HE, Goins EC, Monuszko KA, Kaplan SJ, et al. Treatments and outcomes in high-risk gestational trophoblastic neoplasia: a systematic review and meta-analysis. BJOG. 2023;130(5):443–53. DOI: https://doi.org/10.1111/1471-0528.17374
Flam F. Emergency surgery in gestational trophoblastic tumours. Eur J Obst Gynecol Reprod Biol. 1994;55(3):183–6.
https://doi.org/10.1016/0028-2243(94)90036-1 DOI: https://doi.org/10.1016/0028-2243(94)90036-1
Eysbouts YK, Massuger LFAG, IntHout J, Lok CAR, Sweep FCGJ, Ottevanger PB. The added value of hysterectomy in the management of gestational trophoblastic neoplasia. Gynecol Oncol. 2017;145(3):536–42.
https://doi.org/10.1016/j.ygyno.2017.03.018 DOI: https://doi.org/10.1016/j.ygyno.2017.03.018
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Agnes Larsson, Emelie Wallin, Mats Nilsson, Ulrika Joneborg
This work is licensed under a Creative Commons Attribution 4.0 International License.
